Piper Sandler initiated coverage on Avalo Therapeutics with a new price target
$AVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00